Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: Results of CIBIS II

Henry Krum, Michael Bailey, Wilfried Meyer, Patricia Verkenne, Henry Dargie, Phillipe Lechat, Stefan Anker

Research output: Contribution to journalArticlepeer-review

Abstract

Background: HMG-CoA reductase inhibitors (statins) are widely prescribed in patients with established systolic chronic heart failure (CHF). However, there is considerable controversy regarding their benefit in this setting. We therefore conducted a post-hoc analysis of outcomes according to statin use within the Second Cardiac Insufficiency Bisoprolol Study of the beta-blocker, bisoprolol, in NYHA classes III-IV systolic CHF patients (left ventricular ejection fraction

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalCardiology
Volume108
Issue number1
DOIs
Publication statusPublished - Jun 2007

Keywords

  • Beta-blocker
  • Bisoprolol
  • Chronic heart failure
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: Results of CIBIS II'. Together they form a unique fingerprint.

Cite this